Targeting EGFR therapies such as monoclonal antibodies and EGFR tyrosine kinase inhibitors (EGFR-TKIs) have been developed, which has helped clinicians to identify and treat patient with NPC [20]. Here, EGFR is linked to nasopharyngeal carcinoma.